Cover Image
Market Research Report

Pharma Leader Series - Top 20 Asthma & COPD Companies 2019-2029: Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast

Published by Visiongain Ltd Product code 783076
Published Content info 160 Pages
Delivery time: 1-2 business days
Price
Back to Top
Pharma Leader Series - Top 20 Asthma & COPD Companies 2019-2029: Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast
Published: December 19, 2018 Content info: 160 Pages
Description

The global asthma & COPD therapies market was valued at $36.21bn in 2018 and is projected to grow to $47bn by 2029.

How this report will benefit you:

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 160-page report you will receive 86 charts- all unavailable elsewhere.

The 160-page report provides clear detailed insight into the Top 20 asthma & COPD companies. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Asthma & COPD Therapies Market forecasts from 2019-2029.

Profiles of the leading 20 asthma & COPD companies:

  • Aerocrine (Circassia)
  • ALK-Abello A/S
  • Amphastar Pharmaceuticals, Inc.
  • AstraZeneca
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
  • Cipla
  • GlaxoSmithKline
  • Lallemand Pharma International
  • Merck
  • MundiPharma
  • Novartis
  • Pulmatrix
  • Roche
  • Sanofi/Regeneron
  • Sunovion
  • Teva
  • Theravance Biopharma-Mylan Inc.
  • Vectura Group plc
  • Verona Pharma plc

The content of each profile differs, depending on the organization. In general, a profile gives the following information:

  • An overview and analysis of the company
  • A portfolio of the company's marketed product and product pipeline
  • Financial Information
  • Revenue forecast from 2019-2029
  • Recent developments
  • Future Outlook

This report discusses factors that drive and restrain the asthma and COPD market.

Visiongain's study is intended for anyone requiring commercial analyses for the top 20 asthma & COPD therapies companies. You find data, trends and predictions.

Buy our report today Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029: Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast.

Visiongain is a trading partner with the US Federal Government.

Table of Contents
Product Code: PHA0349

Table of Contents

1. Report Overview

  • 1.1. Global Asthma & COPD Companies Market Overview
  • 1.2. Global Asthma & COPD Companies Market Segmentation
  • 1.3. Why You Should Read this Report
  • 1.4. How this Report Delivers
  • 1.5. Key Questions Answered by this Analytical Report
  • 1.6. Who is This Report for?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Introduction to Asthma & COPD Therapies

  • 2.1. COPD Overview
    • 2.1.1. Chronic Obstructive Pulmonary Disease Medications
  • 2.2. Asthma Overview
    • 2.2.1. Desirable inhaler characteristics for treating asthma
  • 2.3. Asthma & COPD Respiratory Inhalers Overview
    • 2.3.1. Nebulizers
    • 2.3.2. Metered Dose Inhaler
    • 2.3.3. Breath-Actuated Pressurised Metered-Dose Inhalers
    • 2.3.4. Pressurised Metered-Dose Inhalers Plus Spacer Devices
    • 2.3.5. Dry powder inhalers (DPIs)
    • 2.3.6. Soft Mist Inhalers
  • 2.4. Asthma & COPD Therapies-Realising Their Potential, Market Drivers
    • 2.4.1. Combination Therapies-Asthma & COPD Products
    • 2.4.2. Triple Combination-Asthma & COPD Products
    • 2.4.3. Opportunities in Telehealth
  • 2.5. Market Restraints
  • 2.6. Asthma & COPD Products: Trends and Developments
    • 2.6.1. E-Technology in Asthma and COPD

3. Leading Asthma & COPD Companies: Overview, 2018

  • 3.1. The Global Asthma & COPD Companies Market In 2018
  • 3.2. Leading Companies in the Asthma & COPD Market, 2018
  • 3.3. How Will Leading Companies' Market Shares Change to 2029?

4. Leading Asthma & COPD Companies Worldwide, 2018

  • 4.1. Astrazeneca-Company Overview & Analysis
    • 4.1.1. AstraZeneca Marketed Asthma & COPD products
    • 4.1.2. AstraZeneca, Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.1.3. AstraZeneca -Asthma & COPD Market Forecast, 2018-2029
  • 4.2. GlaxoSmithKline-Company Overview & Analysis
    • 4.2.1. GlaxoSmithKline Marketed Asthma & COPD products
    • 4.2.2. GlaxoSmithKline, Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.2.3. GlaxoSmithKline -Asthma & COPD Market Forecast, 2018-2029
  • 4.3. Boehringer Ingelheim-Company Overview & Analysis
    • 4.3.1. Boehringer Ingelheim Marketed Asthma & COPD products
    • 4.3.2. Boehringer Ingelheim, Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.3.3. Boehringer Ingelheim -Asthma & COPD Market Forecast, 2018-2029
  • 4.4. Teva-Company Overview & Analysis
    • 4.4.1. Teva Marketed Asthma & COPD products
    • 4.4.2. Teva, Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.4.3. Teva -Asthma & COPD Market Forecast, 2018-2029
  • 4.5. Merck-Company Overview & Analysis
    • 4.5.1. Merck Marketed Asthma & COPD products
    • 4.5.2. Merck, Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.5.3. Merck -Asthma & COPD Market Forecast, 2018-2029
  • 4.6. Roche-Company Overview & Analysis
    • 4.6.1. Roche Marketed Asthma & COPD products
    • 4.6.2. Roche, Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.6.3. Roche -Asthma & COPD Market Forecast, 2018-2029
  • 4.7. Novartis-Company Overview & Analysis
    • 4.7.1. Novartis Marketed Asthma & COPD products
    • 4.7.2. Novartis, Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.7.3. Novartis -Asthma & COPD Market Forecast, 2018-2029
  • 4.8. Regeneron Pharmaceuticals (Sanofi)- Company Overview & ANALYSIS
    • 4.8.1. Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.8.2. Regeneron Pharmaceuticals (Sanofi) -Asthma & COPD Market Forecast, 2018-2029
  • 4.9. Mundipharma-Company Overview & Analysis
    • 4.9.1. Mundipharma Marketed Asthma & COPD products
    • 4.9.2. Mundipharma, Asthma & COPD Products- R&D Pipeline & Future Outlook
  • 4.10. Theravance Biopharma-Company Overview & Analysis
    • 4.10.1. Theravance Biopharma Marketed Asthma & COPD products
    • 4.10.2. Theravance Biopharma, Asthma & COPD Products- R&D Pipeline & Future Outlook
  • 4.11. Amphastar Pharmaceuticals-Company Overview & Analysis
    • 4.11.1. Amphastar Pharmaceuticals, Asthma & COPD Products- R&D Pipeline & Future Outlook
  • 4.12. Cipla- Company Overview & Analysis
    • 4.12.1. Cipla Marketed Asthma & COPD products
  • 4.13. Sunovion Pharmaceuticals- Company Overview & Analysis
    • 4.13.1. Sunovion Pharmaceuticals: Marketed Asthma & COPD products
    • 4.13.2. Sunovion Pharmaceuticals, Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.13.3. Sunovion -Asthma & COPD Market Forecast, 2018-2029
  • 4.14. Aerocrine (Circassia)- Company Overview & Analysis
    • 4.14.1. Circassia Marketed Asthma & COPD products
    • 4.14.2. Circassia, Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.14.3. Circassia -Asthma & COPD Market Forecast, 2018-2029
  • 4.15. Vectura Group-Company Overview & Analysis
    • 4.15.1. Vectura Group Marketed Asthma & COPD products
    • 4.15.2. Vectura Group, Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.15.3. Vectura Group -Asthma & COPD Market Forecast, 2018-2029
  • 4.16. Lallemand Pharma Ag- Company Overview & Analysis
    • 4.16.1. Lallemand Pharma AG Marketed Asthma & COPD products
    • 4.16.2. Lallemand Pharma AG, Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.16.3. Lallemand Pharma -Asthma & COPD Market Forecast, 2018-2029
  • 4.17. Chiesi Farmaceutici S.P.A.-Company Overview & Analysis
    • 4.17.1. Chiesi Farmaceutici S.p.A Marketed Asthma & COPD Products
    • 4.17.2. Chiesi Farmaceutici, Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.17.3. Chiesi Farmaceutici: -Asthma & COPD Market Forecast, 2018-2029
  • 4.18. Pulmatrix: Company Overview & Analysis
    • 4.18.1. Pulmatrix, Asthma & COPD Products- R&D Pipeline & Future Outlook
  • 4.19. Verona Pharma Plc- Company Overview & Analysis
    • 4.19.1. Verona Pharma plc, Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.19.2. Verona Pharma plc -Asthma & COPD Market Forecast, 2018-2029
  • 4.20. Alk-Abelló A/S- Company Overview & Analysis
    • 4.20.1. ALK-Abelló A/S Marketed Asthma & COPD Products
    • 4.20.2. ALK-Abelló A/S, Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.20.3. ALK-Abelló A/S -Asthma & COPD Market Forecast, 2018-2029

5. Conclusions

  • 5.1. Asthma & COPD Products: A Maturing Market
  • 5.2. The Global Asthma & COPD Companies Market In 2019
  • 5.3. Leading Asthma & COPD Companies
  • 5.4. Global Asthma & COPD Products Market Forecast 2019-2029
  • 5.5. The Future of The Asthma & COPD Products Market
    • 5.5.1. Growth in Anti-Inflammatory and Combination Drugs
    • 5.5.2. Personalised Medicine
    • 5.5.3. Unmet Needs in Asthma and COPD
  • 5.6. Strategies for Growth in 2018-2029

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 2.1: Advantages and Disadvantages of the Main Types of Asthma Inhalers
  • Table 2.2: E-Technology Based Inhalers
  • Table 3.1: Global Market Forecast: Revenues ($bn), AGR (%) By Leading Companies, 2018-2029
  • Table 3.2: Leading Companies in Asthma & COPD diseases
  • Table 3.3: Leading Asthma & COPD Companies: Revenues ($bn) and Market Shares (%), 2019 And 2029
  • Table 4.1: Astrazeneca: Company Overview
  • Table 4.2: Astrazeneca: Products Portfolio
  • Table 4.3: Astrazeneca: Products Pipeline Portfolio
  • Table 4.4: Astrazeneca: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 4.5: Glaxosmithkline: Company Overview
  • Table 4.6: Glaxosmithkline: Products Portfolio
  • Table 4.7: Glaxosmithkline: Products Pipeline Portfolio
  • Table 4.8: Glaxosmithkline: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 4.9: Boehringer Ingelheim: Company Overview
  • Table 4.10: Boehringer Ingelheim: Products Portfolio
  • Table 4.11: Boehringer Ingelheim: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 4.12: Teva: Company Overview
  • Table 4.13: Teva: Products Portfolio
  • Table 4.14: Teva: Products Pipeline Portfolio
  • Table 4.15: Teva: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 4.16: Merck: Company Overview
  • Table 4.17: Merck: Products Portfolio
  • Table 4.18: Merck: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 4.19: Roche: Company Overview
  • Table 4.20: Roche: Products Portfolio
  • Table 4.21: Roche: Products Pipeline Portfolio
  • Table 4.22: Roche: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 4.23: Novartis: Company Overview
  • Table 4.24: Novartis: Products Portfolio
  • Table 4.25: Novartis: Products Pipeline Portfolio
  • Table 4.26: Novartis: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 4.27: Regeneron Pharmaceuticals (Sanofi): Company Overview
  • Table 4.28: Regeneron Pharmaceuticals (Sanofi): Product Pipeline Portfolio
  • Table 4.29: Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 4.30: Mundipharma: Company Overview
  • Table 4.31: Mundipharma: Products Portfolio
  • Table 4.32: Mundipharma: Products Pipeline Portfolio
  • Table 4.33: Theravance Biopharma: Company Overview
  • Table 4.34: Theravance Biopharma: Products Portfolio
  • Table 4.35: Theravance Biopharma: Products Pipeline Portfolio
  • Table 4.36: Amphastar Pharmaceuticals: Company Overview
  • Table 4.37: Amphastar Pharmaceuticals: Products Pipeline Portfolio
  • Table 4.38: Cipla: Company Overview
  • Table 4.39: Cipla: Products Portfolio
  • Table 4.40: Sunovion Pharmaceuticals: Company Overview
  • Table 4.41: Sunovion Pharmaceuticals: Products Portfolio
  • Table 4.42: Sunovion: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 4.43: Circassia: Company Overview
  • Table 4.44: Circassia: Products Portfolio
  • Table 4.45: Circassia: Products Pipeline Portfolio
  • Table 4.46: Vectura Group: Company Overview
  • Table 4.47: Vectura Group: Products Portfolio
  • Table 4.48: Vectura Group: Products Pipeline Portfolio
  • Table 4.49: Lallemand Pharma AG: Company Overview
  • Table 4.50: Lallemand Pharma AG: Products Portfolio
  • Table 4.51: Lallemand Pharma AG: Products Pipeline Portfolio
  • Table 4.52: Chiesi Farmaceutici S.P.A: Company Overview
  • Table 4.53: Chiesi Farmaceutici S.P.A: Products Portfolio
  • Table 4.54: Chiesi Farmaceutici S.P.A: Products Pipeline Portfolio
  • Table 4.55: Chiesi Farmaceutici S.P.A: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
  • Table 4.56: Pulmatrix: Company Overview
  • Table 4.57: Pulmatrix: Products Pipeline Portfolio
  • Table 4.58: Verona Pharma Plc: Company Overview
  • Table 4.59: Verona Pharma Plc: Products Pipeline Portfolio
  • Table 4.60: Alk-Abelló A/S: Company Overview
  • Table 4.61: Alk-Abelló A/S Products Portfolio
  • Table 4.62: Alk-Abelló A/S: Products Pipeline Portfolio

List of Figures

  • Figure 1.1: Global Asthma & COPD Companies Market Segmentation Overview, 2019
  • Figure 2.1: Stepwise Approach to Treatment of COPD
  • Figure 2.2: Stepwise Approach to Treatment of Asthma
  • Figure 3.1: Global: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
  • Figure 3.2: Leading Asthma & COPD Drug Manufacturers: Revenue ($bn), 2019
  • Figure 3.3: Leading Asthma & COPD Drug Manufacturers: Market Share (%), 2019
  • Figure 3.4: Leading Asthma & COPD Companies: Revenues ($bn), 2029
  • Figure 3.5: Leading Asthma & COPD Companies: Market Shares (%), 2029
  • Figure 4.1: AstraZeneca: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
  • Figure 4.2: GlaxoSmithKline: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
  • Figure 4.3: Boehringer Ingelheim: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
  • Figure 4.4: Teva: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
  • Figure 4.5: Merck: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
  • Figure 4.6: Roche: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
  • Figure 4.7: Novartis: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
  • Figure 4.8: Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
  • Figure 4.9: Sunovion Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
  • Figure 4.10: Chiesi Farmaceutici Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
  • Figure 5.1: World Asthma & COPD Products Market Forecast: Revenues ($bn), 2019-2029

COMPANIES LISTED:

  • Aerocrine (Circassia)
  • ALK-Abello A/S
  • American College of Chest Physicians (ACCP)
  • Amphastar Pharmaceuticals, Inc.
  • AstraZeneca
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
  • Ciba-Geigy
  • Cipla
  • Committee for Medicinal Products for Human Use (CHMP)
  • Dainippon Sumitomo Pharma America, Inc.
  • Dermira Inc.
  • European Medicines Agency (EMA)
  • European Respiratory Society (ERS)
  • GlaxoSmithKline (GSK)
  • Glenmark
  • Hikma
  • Innovata plc
  • Innoviva, Inc.
  • Japanese Ministry of Health, Labour and Welfare
  • Lallemand Pharma International
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • Merck
  • Monitored Therapeutics, Inc. (MTI)
  • MundiPharma
  • Mylan
  • National Institute for Health and Care Excellence (NICE)
  • Novartis
  • Pulmatrix
  • Regeneron
  • Roche
  • Sandoz
  • Sanofi
  • Sepracor Inc.
  • Sorrento
  • Sunovion
  • Teva
  • Theravance Biopharma-Mylan Inc.
  • Torii
  • Vectura Group plc
  • Verona Pharma plc
Back to Top